LKB1 as a tumor suppressor in uterine cancer: Mouse models and translational studies

Christopher G. Peña, Diego H. Castrillón

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The LKB1 tumor suppressor was identifi ed in 1998 as the gene mutated in the Peutz–Jeghers Syndrome (PJS), a hereditary cancer predisposition characterized by gastrointestinal polyposis and a high incidence of cancers, particularly carcinomas, at a variety of anatomic sites including the gastrointestinal tract, lung, and female reproductive tract. Women with PJS have a high incidence of carcinomas of the uterine corpus (endometrium) and cervix. The LKB1 gene is also somatically mutated in human cancers arising at these sites. Work in mouse models has highlighted the potency of LKB1 as an endometrial tumor suppressor and its distinctive roles in driving invasive and metastatic growth. These in vivo models represent tractable experimental systems for the discovery of underlying biological principles and molecular processes regulated by LKB1 in the context of tumorigenesis and also serve as useful preclinical model systems for experimental therapeutics. Here we review LKB1’s known roles in mTOR signaling, metabolism, and cell polarity, with an emphasis on human pathology and mouse models relevant to uterine carcinogenesis, including cancers of the uterine corpus and cervix.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages211-241
Number of pages31
Volume943
DOIs
StatePublished - Jan 1 2017

Publication series

NameAdvances in Experimental Medicine and Biology
Volume943
ISSN (Print)00652598
ISSN (Electronic)22148019

Fingerprint

Uterine Neoplasms
Tumors
Neoplasms
Carcinogenesis
Genes
Hereditary Neoplastic Syndromes
Carcinoma
Cell Polarity
Incidence
Pathology
Endometrium
Metabolism
Cervix Uteri
Uterine Cervical Neoplasms
Gastrointestinal Tract
Theoretical Models
Lung
Growth
Therapeutics

Keywords

  • AMPK
  • Endometrial cancer
  • Genetically engineered mouse models
  • LKB1
  • MTOR
  • STK11
  • Therapeutics
  • Uterine cancer

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Peña, C. G., & Castrillón, D. H. (2017). LKB1 as a tumor suppressor in uterine cancer: Mouse models and translational studies. In Advances in Experimental Medicine and Biology (Vol. 943, pp. 211-241). (Advances in Experimental Medicine and Biology; Vol. 943). Springer New York LLC. https://doi.org/10.1007/978-3-319-43139-0_7

LKB1 as a tumor suppressor in uterine cancer : Mouse models and translational studies. / Peña, Christopher G.; Castrillón, Diego H.

Advances in Experimental Medicine and Biology. Vol. 943 Springer New York LLC, 2017. p. 211-241 (Advances in Experimental Medicine and Biology; Vol. 943).

Research output: Chapter in Book/Report/Conference proceedingChapter

Peña, CG & Castrillón, DH 2017, LKB1 as a tumor suppressor in uterine cancer: Mouse models and translational studies. in Advances in Experimental Medicine and Biology. vol. 943, Advances in Experimental Medicine and Biology, vol. 943, Springer New York LLC, pp. 211-241. https://doi.org/10.1007/978-3-319-43139-0_7
Peña CG, Castrillón DH. LKB1 as a tumor suppressor in uterine cancer: Mouse models and translational studies. In Advances in Experimental Medicine and Biology. Vol. 943. Springer New York LLC. 2017. p. 211-241. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-3-319-43139-0_7
Peña, Christopher G. ; Castrillón, Diego H. / LKB1 as a tumor suppressor in uterine cancer : Mouse models and translational studies. Advances in Experimental Medicine and Biology. Vol. 943 Springer New York LLC, 2017. pp. 211-241 (Advances in Experimental Medicine and Biology).
@inbook{1664cb87f515486a9b0a6f27951e9730,
title = "LKB1 as a tumor suppressor in uterine cancer: Mouse models and translational studies",
abstract = "The LKB1 tumor suppressor was identifi ed in 1998 as the gene mutated in the Peutz–Jeghers Syndrome (PJS), a hereditary cancer predisposition characterized by gastrointestinal polyposis and a high incidence of cancers, particularly carcinomas, at a variety of anatomic sites including the gastrointestinal tract, lung, and female reproductive tract. Women with PJS have a high incidence of carcinomas of the uterine corpus (endometrium) and cervix. The LKB1 gene is also somatically mutated in human cancers arising at these sites. Work in mouse models has highlighted the potency of LKB1 as an endometrial tumor suppressor and its distinctive roles in driving invasive and metastatic growth. These in vivo models represent tractable experimental systems for the discovery of underlying biological principles and molecular processes regulated by LKB1 in the context of tumorigenesis and also serve as useful preclinical model systems for experimental therapeutics. Here we review LKB1’s known roles in mTOR signaling, metabolism, and cell polarity, with an emphasis on human pathology and mouse models relevant to uterine carcinogenesis, including cancers of the uterine corpus and cervix.",
keywords = "AMPK, Endometrial cancer, Genetically engineered mouse models, LKB1, MTOR, STK11, Therapeutics, Uterine cancer",
author = "Pe{\~n}a, {Christopher G.} and Castrill{\'o}n, {Diego H.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-3-319-43139-0_7",
language = "English (US)",
volume = "943",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer New York LLC",
pages = "211--241",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - LKB1 as a tumor suppressor in uterine cancer

T2 - Mouse models and translational studies

AU - Peña, Christopher G.

AU - Castrillón, Diego H.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The LKB1 tumor suppressor was identifi ed in 1998 as the gene mutated in the Peutz–Jeghers Syndrome (PJS), a hereditary cancer predisposition characterized by gastrointestinal polyposis and a high incidence of cancers, particularly carcinomas, at a variety of anatomic sites including the gastrointestinal tract, lung, and female reproductive tract. Women with PJS have a high incidence of carcinomas of the uterine corpus (endometrium) and cervix. The LKB1 gene is also somatically mutated in human cancers arising at these sites. Work in mouse models has highlighted the potency of LKB1 as an endometrial tumor suppressor and its distinctive roles in driving invasive and metastatic growth. These in vivo models represent tractable experimental systems for the discovery of underlying biological principles and molecular processes regulated by LKB1 in the context of tumorigenesis and also serve as useful preclinical model systems for experimental therapeutics. Here we review LKB1’s known roles in mTOR signaling, metabolism, and cell polarity, with an emphasis on human pathology and mouse models relevant to uterine carcinogenesis, including cancers of the uterine corpus and cervix.

AB - The LKB1 tumor suppressor was identifi ed in 1998 as the gene mutated in the Peutz–Jeghers Syndrome (PJS), a hereditary cancer predisposition characterized by gastrointestinal polyposis and a high incidence of cancers, particularly carcinomas, at a variety of anatomic sites including the gastrointestinal tract, lung, and female reproductive tract. Women with PJS have a high incidence of carcinomas of the uterine corpus (endometrium) and cervix. The LKB1 gene is also somatically mutated in human cancers arising at these sites. Work in mouse models has highlighted the potency of LKB1 as an endometrial tumor suppressor and its distinctive roles in driving invasive and metastatic growth. These in vivo models represent tractable experimental systems for the discovery of underlying biological principles and molecular processes regulated by LKB1 in the context of tumorigenesis and also serve as useful preclinical model systems for experimental therapeutics. Here we review LKB1’s known roles in mTOR signaling, metabolism, and cell polarity, with an emphasis on human pathology and mouse models relevant to uterine carcinogenesis, including cancers of the uterine corpus and cervix.

KW - AMPK

KW - Endometrial cancer

KW - Genetically engineered mouse models

KW - LKB1

KW - MTOR

KW - STK11

KW - Therapeutics

KW - Uterine cancer

UR - http://www.scopus.com/inward/record.url?scp=85006013749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006013749&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-43139-0_7

DO - 10.1007/978-3-319-43139-0_7

M3 - Chapter

C2 - 27910069

AN - SCOPUS:85006013749

VL - 943

T3 - Advances in Experimental Medicine and Biology

SP - 211

EP - 241

BT - Advances in Experimental Medicine and Biology

PB - Springer New York LLC

ER -